In Vitro and Vivo Experiments Revealing Astragalin Inhibited Lung Adenocarcinoma Development via LINC00582/miR‐140‐3P/PDPK1
Journal of Biochemical and Molecular Toxicology · 2024
DOI: 10.1002/jbt.70042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2024. Verfasst von Juncheng Bai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Inner Mongolia University for Nationalities Affiliated Hospital, Tongliao, China. Hauptthemen laut MEDLINE: MicroRNAs, Lung Neoplasms, Adenocarcinoma of Lung, RNA, Long Noncoding. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
This study aimed to explore the mechanism of the development of lung adenocarcinoma (LUAD) treated by astragalin. Transcriptome sequencing was performed to obtain the gene profile of LUAD treated by astragalin. Combining with bioinformatics analysis including differential gene screening, function enrichment analysis (gene ontology and KEGG), and ceRNA construction, we obtained the novel mechanism of lncRNA mediated miRNA/mRNA axis. Then, the cell experiments were performed to examine the role of lncRNA in cell proliferation, migration and invasion, and apoptosis for LUAD treated with astragalin. Moreover, the tumor formation in nude mice was carried out to detect the ceRNA mechanism in LUAD treated by astragalin in vivo. The lncRNA mediated ceRNA network was obtained, that is, LINC00852 LINC00582/miR‐140‐3p/PDPK1 played an important role in LUAD treated by astragalin. Function experiments indicated that si‐LINC00852 inhibited LUAD cell proliferation, migration and invasion, and promoted cell apoptosis via miR‐140‐3p/PDPK1 ( p < 0.05, p < 0.01). The animal experiments further confirmed that si‐LINC00852 inhibited tumor growth through miR‐140‐3p/PDPK1 in vivo. Conversely, this study provides comprehensive insights into the diagnostic and therapeutic implications of LINC00582 in LUAD, LINC00582 mediated miR‐140‐3p/PDPK1 axis was the novel drug target of astragalin for treating LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Inner Mongolia University for Nationalities Affiliated Hospital, Tongliao, China.
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Bai, J., Chen, Y., Zhao, G., & Gui, R. (2024). In Vitro and Vivo Experiments Revealing Astragalin Inhibited Lung Adenocarcinoma Development via LINC00582/miR‐140‐3P/PDPK1. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70042
Vancouver
Bai J, Chen Y, Zhao G, Gui R. In Vitro and Vivo Experiments Revealing Astragalin Inhibited Lung Adenocarcinoma Development via LINC00582/miR‐140‐3P/PDPK1. Journal of Biochemical and Molecular Toxicology. 2024. doi:10.1002/jbt.70042
BibTeX
@article{Bai2024,
author = {Bai, Juncheng and Chen, Yuxin and Zhao, Geyu and Gui, Rong},
title = {In Vitro and Vivo Experiments Revealing Astragalin Inhibited Lung Adenocarcinoma Development via LINC00582/miR‐140‐3P/PDPK1},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2024},
doi = {10.1002/jbt.70042}
}
EUVIMED